Promoted Content
Promoted Content

Find Novel Gastroenterology Drugs in Preclinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Gastroenterology Product Name: PGN-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            Progenity has two lead drug-device candidates utilizing the DDS technology, PGN-001, a high-concentration formulation of adalimumab, and PGN-600 a liquid formulation of tofacitinib, both under development for the treatment of ulcerative colitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PN-235

            Therapeutic Area: Gastroenterology Product Name: JNJ-77242113

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 29, 2020

            Details:

            The two new candidates, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), are being developed as part of a portfolio strategy of discovering and developing oral IL-23 receptor antagonists.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNSP003

            Therapeutic Area: Gastroenterology Product Name: SNSP003

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: CF Foundation

            Deal Size: $22.5 Million Upfront Cash: $14.0 million

            Deal Type: Funding October 20, 2020

            Details:

            The new funding will be used to advance preclinical development and early stage clinical trials for Synspira’s non-porcine enzyme replacement therapy, SNSP003.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALV-304

            Therapeutic Area: Gastroenterology Product Name: ALV-304

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $3.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 05, 2020

            Details:

            The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RTX-1688

            Therapeutic Area: Gastroenterology Product Name: RTX-1688

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PR600

            Therapeutic Area: Gastroenterology Product Name: PR600

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Dr. Falk Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 13, 2020

            Details:

            Under the terms of the agreement, Prometheus and Falk will share responsibility for the global development of PR600, with Falk contributing one-quarter of the costs associated with developing PR600.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-057

            Therapeutic Area: Gastroenterology Product Name: MORF-057

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            The data presented at DDW demonstrate that MORF-057 successfully targets the integrin α4β7 with high potency and selectivity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Synthetic Biotic medicines

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination May 21, 2020

            Details:

            Upon termination, Synlogic regains all rights to develop Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MORF-057

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 14, 2020

            Details:

            Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALPN-101

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.